Searched for: in-biosketch:true
person:segevd01
Beyond insurance status: the impact of Medicaid expansion on the diagnosis of Hepatocellular Carcinoma
Papageorge, Marianna V; Woods, Alison P; de Geus, Susanna W L; Ng, Sing Chau; Paasche-Orlow, Michael K; Segev, Dorry; McAneny, David; Kenzik, Kelly M; Sachs, Teviah E; Tseng, Jennifer F
BACKGROUND:Medicaid expansion has led to earlier stage diagnoses in several cancers but has not been studied in hepatocellular carcinoma (HCC), a disease with complex risk factors. We examined the effect of Medicaid expansion on the diagnosis of HCC and associations with county-level social vulnerability. METHODS:Patients with HCC <65 years of age were identified from the SEER database (2010-2016). County-level social vulnerability factors were obtained from the CDC SVI and BRFSS. A Difference-in-Difference analysis evaluated change in early-stage diagnoses (stage I-II) between expansion and non-expansion states. A Difference-in-Difference-in-Difference analysis evaluated expansion impact among counties with higher proportions of social vulnerability. RESULTS:Of 19,751 patients identified, 81.5% were in expansion states. Uninsured status decreased in expansion states (6.3%-2.4%, p < 0.0001) and remained unchanged in non-expansion states (12.7%-14.8%, p = 0.43). There was no significant difference in the incidence of early-stage diagnoses between expansion states and non-expansion states. Results were consistent when accounting for social vulnerability. CONCLUSION/CONCLUSIONS:Medicaid expansion was not associated with earlier stage diagnoses in patients with HCC, including those with higher social vulnerability. Unlike other cancers, expanded access did not translate into higher utilization of care in HCC, suggesting barriers on a multitude of levels.
PMID: 35042672
ISSN: 1477-2574
CID: 5127902
Hurricanes and Mortality among Patients Receiving Dialysis
Blum, Matthew F; Feng, Yijing; Anderson, G Brooke; Segev, Dorry L; McAdams-DeMarco, Mara; Grams, Morgan E
BACKGROUND:Hurricanes are severe weather events that can disrupt power, water, and transportation systems. These disruptions may be deadly for patients requiring maintenance dialysis. We hypothesized that the mortality risk among patients requiring maintenance dialysis would be increased in the 30 days after a hurricane. METHODS:Patients registered as requiring maintenance dialysis in the United States Renal Data System who initiated treatment between January 1, 1997 and December 31, 2017 in one of 108 hurricane-afflicted counties were followed from dialysis initiation until transplantation, dialysis discontinuation, a move to a nonafflicted county, or death. Hurricane exposure was determined as a tropical cyclone event with peak local wind speeds ≥64 knots in the county of a patient's residence. The risk of death after the hurricane was estimated using time-varying Cox proportional hazards models. RESULTS:The median age of the 187,388 patients was 65 years (IQR, 53-75) and 43.7% were female. There were 27 hurricanes and 105,398 deaths in 529,339 person-years of follow-up on dialysis. In total, 29,849 patients were exposed to at least one hurricane. Hurricane exposure was associated with a significantly higher mortality after adjusting for demographic and socioeconomic covariates (hazard ratio, 1.13; 95% confidence interval, 1.05-1.22). The association persisted when adjusting for seasonality. CONCLUSIONS:Patients requiring maintenance dialysis have a higher mortality risk in the 30 days after a hurricane.
PMID: 35835459
ISSN: 1533-3450
CID: 5279972
Immunogenicity of Ad26.COV2.S prime and two subsequent doses of mRNA SARS-CoV-2 vaccines in solid organ transplant recipients: A case series [Letter]
Chang, Amy; Mitchell, Jonathan; Alejo, Jennifer L; Chiang, Teresa P Y; Abedon, Aura T; Kim, Jake D; Avery, Robin K; Tobian, Aaron A R; Levan, Macey L; Warren, Daniel S; Garonzik-Wang, Jacqueline M; Massie, Allan B; Segev, Dorry L; Werbel, William A
PMID: 35822545
ISSN: 1399-0012
CID: 5279872
Clinical Protection During the First Omicron Wave in Unvaccinated, Convalescent US Adults-Reply [Comment]
Alejo, Jennifer L; Makary, Martin A; Segev, Dorry L
PMID: 35819425
ISSN: 1538-3598
CID: 5279852
Defining the ethical considerations surrounding kidney transplantation for frail and cognitively impaired patients: a Delphi study of geriatric transplant experts
Shrestha, Prakriti; Van Pilsum Rasmussen, Sarah E; King, Elizabeth A; Gordon, Elisa J; Faden, Ruth R; Segev, Dorry L; Humbyrd, Casey Jo; McAdams-DeMarco, Mara
BACKGROUND:Among adult kidney transplant (KT) candidates, 21% are frail and 55% have cognitive impairment, increasing the risk of pre- and post-KT mortality. Centers often assess frailty status and cognitive function during transplant evaluation to help identify appropriate candidate. Yet, there are no ethical guidelines regarding the use of frailty and cognitive function during this evaluation. We seek to develop a clinical consensus on balancing utility and justice in access to KT for frail and cognitively impaired patients. METHODS:Twenty-seven experts caring for ESRD patients completed a two-round Delphi panel designed to facilitate consensus (> 80% agreement). RESULTS:Experts believed that denying patients transplantation based solely on expected patient survival was inequitable to frail or cognitively impaired candidates; 100% agreed that frailty and cognitive impairment are important factors to consider during KT evaluation. There was consensus that health related quality of life and social support are important to consider before waitlisting frail or cognitively impaired patients. Experts identified important factors to consider before waitlisting frail (likely to benefit from KT, frailty reversibility, age, and medical contraindications) and cognitively impaired (degree of impairment and medication adherence) patients. CONCLUSIONS:Clinical experts believed it was ethically unacceptable to allocate organs solely based on patients' expected survival; frailty and cognitive impairment should be measured at evaluation when weighed against other clinical factors. Ethical guidelines regarding the use of frailty and cognitive function during KT evaluation ought to be developed.
PMCID:9264705
PMID: 35804289
ISSN: 1471-2318
CID: 5267972
Antibody Response to a Fourth Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: An Update
Mitchell, Jonathan; Alejo, Jennifer L; Chiang, Teresa P Y; Kim, Jake; Chang, Amy; Abedon, Aura T; Avery, Robin K; Tobian, Aaron A R; Massie, Allan B; Levan, Macey L; Warren, Daniel S; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Werbel, William A
PMID: 35426888
ISSN: 1534-6080
CID: 5204472
A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response
Karaba, Andrew H; Johnston, Trevor S; Aytenfisu, Tihitina Y; Akinde, Olivia; Eby, Yolanda; Ruff, Jessica E; Abedon, Aura T; Alejo, Jennifer L; Blankson, Joel N; Cox, Andrea L; Bailey, Justin R; Klein, Sabra L; Pekosz, Andrew; Segev, Dorry L; Tobian, Aaron A R; Werbel, William A
Background:Humoral responses to coronavirus disease 2019 (COVID-19) vaccines are attenuated in solid organ transplant recipients (SOTRs), necessitating additional booster vaccinations. The Omicron variant demonstrates substantial immune evasion, and it is unknown whether additional vaccine doses increase neutralizing capacity versus this variant of concern (VOC) among SOTRs. Methods:Within an observational cohort, 25 SOTRs with low seroresponse underwent anti-severe acute respiratory syndrome coronavirus 2 spike and receptor-binding domain immunoglobulin (Ig)G testing using a commercially available multiplex ELISA before and after a fourth COVID-19 vaccine dose (D4). Surrogate neutralization (percent angiotensin-converting enzyme 2 inhibition [%ACE2i], range 0%-100% with >20% correlating with live virus neutralization) was measured against full-length spike proteins of the vaccine strain and 5 VOCs including Delta and Omicron. Changes in IgG level and %ACE2i were compared using the paired Wilcoxon signed-rank test. Results:Anti-receptor-binding domain and anti-spike seropositivity increased post-D4 from 56% to 84% and 68% to 88%, respectively. Median (interquartile range) anti-spike antibody significantly increased post-D4 from 42.3 (4.9-134.2) to 228.9 (1115.4-655.8) World Health Organization binding antibody units. %ACE2i (median [interquartile range]) also significantly increased against the vaccine strain (5.8% [0%-16.8%] to 20.6% [5.8%-45.9%]) and the Delta variant (9.1% [4.9%-12.8%] to 17.1% [10.3%-31.7%]), yet neutralization versus Omicron was poor, did not increase post-D4 (4.1% [0%-6.9%] to 0.5% [0%-5.7%]), and was significantly lower than boosted healthy controls. Conclusions:Although a fourth vaccine dose increases anti-spike IgG and neutralizing capacity against many VOCs, some SOTRs may remain at high risk for Omicron infection despite boosting. Thus, additional protective interventions or alternative vaccination strategies should be urgently explored.
PMID: 35417115
ISSN: 1534-6080
CID: 5219052
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
Frey, Sarah; Chowdhury, Reezwana; Connolly, Caoilfhionn M; Werbel, William A; Segev, Dorry L; Parian, Alyssa M; Tsipotis, Evangelos; Dudley-Brown, Sharon; Lazarev, Mark; Melia, Joanna M; Truta, Brindusa; Yu, Huimin; Selaru, Florin M
PMCID:8732901
PMID: 34998996
ISSN: 1542-7714
CID: 5127872
Increasing rates of parathyroidectomy to treat secondary hyperparathyroidism in dialysis patients with Medicare coverage
Mathur, Aarti; Ahn, JiYoon B; Sutton, Whitney; Zeiger, Martha A; Segev, Dorry L; McAdams-DeMarco, Mara
BACKGROUND:Secondary hyperparathyroidism affects nearly all patients with renal failure on dialysis. Medical treatment of secondary hyperparathyroidism has considerably evolved over the past 2 decades, with parathyroidectomy reserved for severe cases. The primary objective of our study was to understand how trends in medical treatments affected parathyroidectomy rates in patients with secondary hyperparathyroidism on dialysis. METHODS:We used the United States Renal Data System to identify 379,835 adult patients (age ≥18) who were on maintenance dialysis in the United States between 2006 and 2016 with Medicare as the primary payor and ascertained treatment for secondary hyperparathyroidism. Adjusted rate ratios for rates of parathyroidectomy were calculated using multivariable-adjusted Poisson regression. RESULTS:Of 379,835 secondary hyperparathyroidism patients, 4,118 (1.1%) underwent parathyroidectomy, 39,835 (10.5%) received cinacalcet, 243,522 (64.1%) received phosphate binders, 17,571 (4.6%) received vitamin D analogs, and 86,899 (22.9%) received no treatment during the 10 years of follow-up. Over the entire study period, there was a 3.5-fold increase in the use of calcimimetics and a 3.4-fold increase in rates of parathyroidectomy. Compared to 2006 through 2009, utilization of parathyroidectomy increased 52% (adjusted rate ratio = 1.52, 95% confidence interval: 1.39-1.65) between 2010 and 2013 and by 106% (adjusted rate ratio = 2.06, 95% confidence interval: 1.90-2.24) between 2014 and 2016. The greatest increase in parathyroidectomy utilization occurred in younger patients (age 18-64 years), Black patients, female patients, those living in higher poverty neighborhoods, those listed for kidney transplant, and those who live in the Southern region of the United States. CONCLUSION:Despite the evolution of medical treatments and an increase in the use of calcimimetics to treat secondary hyperparathyroidism, parathyroidectomy rates have been steadily increasing among dialysis patients with Medicare coverage.
PMID: 35314072
ISSN: 1532-7361
CID: 5806452
National Landscape of HIV+ Deceased Organ Donors in the United States
Werbel, William A; Brown, Diane M; Kusemiju, Oyinkansola T; Doby, Brianna L; Seaman, Shanti M; Redd, Andrew D; Eby, Yolanda; Fernandez, Reinaldo E; Desai, Niraj M; Miller, Jernelle; Bismut, Gilad A; Kirby, Charles S; Schmidt, Haley A; Clarke, William A; Seisa, Michael; Petropoulos, Christos J; Quinn, Thomas C; Florman, Sander S; Huprikar, Shirish; Rana, Meenakshi M; Friedman-Moraco, Rachel J; Mehta, Aneesh K; Stock, Peter G; Price, Jennifer C; Stosor, Valentina; Mehta, Shikha G; Gilbert, Alexander J; Elias, Nahel; Morris, Michele I; Mehta, Sapna A; Small, Catherine B; Haidar, Ghady; Malinis, Maricar; Husson, Jennifer S; Pereira, Marcus R; Gupta, Gaurav; Hand, Jonathan; Kirchner, Varvara A; Agarwal, Avinash; Aslam, Saima; Blumberg, Emily A; Wolfe, Cameron R; Myer, Kevin; Wood, R Patrick; Neidlinger, Nikole; Strell, Sara; Shuck, Marion; Wilkins, Harry; Wadsworth, Matthew; Motter, Jennifer D; Odim, Jonah; Segev, Dorry L; Durand, Christine M; Tobian, Aaron A R
BACKGROUND:Organ transplantation from donors with HIV to recipients with HIV (HIV D+/R+) presents risks of donor-derived infections. Understanding clinical, immunologic, and virologic characteristics of HIV+ donors is critical for safety. METHODS:We performed a prospective study of donors with HIV-positive and HIV false-positive (FP) testing within the HOPE in Action studies of HIV D+/R+ transplantation (ClinicalTrials.gov NCT02602262; NCT03500315; NCT03734393). We compared clinical characteristics in HIV+ versus FP donors. We measured CD4+ T cells, HIV viral load (VL), drug resistance mutations (DRMs), co-receptor tropism, and serum antiretroviral therapy (ART) detection using mass spectrometry in HIV+ donors. RESULTS:Between 03/2016-03/2020, 92 donors (58 HIV+, 34 FP), representing 98.9% of all US HOPE donors during this period, donated 177 organs (131 kidney, 46 liver). Each year the number of donors increased. Prevalence of hepatitis B (16% vs. 0%), syphilis (16% vs. 0%), and cytomegalovirus (91% vs. 58%) was higher in HIV+ versus FP donors; hepatitis C viremia was similar (2% vs. 6%). Most HIV+ donors (71%) had known HIV diagnosis, of whom 90% were prescribed ART and 68% had VL<400 copies/mL. Median CD4 count was 194 cells/uL (IQR=77-331); median CD4% was 27.0 (IQR=16.8-36.1). Major HIV DRMs were detected in 42%, including non-nucleoside reverse transcriptase inhibitors (33%), integrase strand transfer inhibitor (INSTI, 4%), and multiclass (13%). Serum ART was detected in 46% and matched ART by history. CONCLUSION/CONCLUSIONS:Utilization of HIV+ donor organs is increasing. HIV DRMs are common, yet resistance that would compromise INSTI-based regimens is rare, which is reassuring regarding safety.
PMID: 34453519
ISSN: 1537-6591
CID: 5127552